Global Biologics Market Overview:
A biologic drug (biologic) is a chemical derived from or containing components of living organisms. For the manufacture of new biologics, new technologies and novel therapies are emerging, indicating that the global biologics market has a bright future. Biologics are widely utilized to treat, diagnose, and cure a wide range of ailments, including cancer, chronic renal disease, autoimmune disorders, and infectious infections. Patenting, testing, safety, efficacy, and marketing are only a few of the laws and regulations that apply to biologics. Biotechnological approaches and other cutting-edge technologies are used to isolate biologics products from natural sources such as humans, animals, and microorganisms.
|Unit||Value (USD Million)|
|Key Companies Profiled||Merck & Co., Inc. (United States), AbbVie Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Johnson & Johnson (United States), Pfizer Inc. (United States), AstraZeneca (United Kingdom), ABLbio (South Korea), Adimmune (Taiwan), Helius (India) and Innovent Biologics (China)|
|Customization Scope||Avail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility|
- The rise in the Robust Pipeline of Biologics
- Chronic Disease Incidence and Diagnosis are on the Rise across the Globe
- Increased Global Adoption of Novel Biologics Drugs and Therapies
- Clinical Trials with High Strictness and Low Turnover
- Biologics Are Costly and Never Get Refunded
- Increases Funding In Developing Country
- Increasing Drug Manufactures In Developing Country
- Strict Government Regulation
- Issues with Drug Molecule Structure Complexity in Biologics
There are several main participants in the biologics market, which is moderately competitive. Certain strategic activities, such as mergers, new product launches, acquisitions, and collaborations, are being implemented by the firms to help them increase their market positions. Due to the high cost of biologics, these businesses have made significant capital investments in biologics research and development.
Some of the key players profiled in the report are Merck & Co., Inc. (United States), AbbVie Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Johnson & Johnson (United States), Pfizer Inc. (United States), AstraZeneca (United Kingdom), ABLbio (South Korea), Adimmune (Taiwan), Helius (India) and Innovent Biologics (China). Additionally, following companies can also be profiled that are part of our coverage like Bio-Thera (China), Hisun Pharma (China) and 3SBio (China). Analyst at AMA Research see United States Players to retain maximum share of Global Biologics market by 2027. Considering Market by Drug Type, the sub-segment i.e. Branded Drugs will boost the Biologics market. Considering Market by End-User, the sub-segment i.e. Hospital Pharmacies will boost the Biologics market.
In April 2021, Novartis AG (Sandoz) and Bio-Thera Solutions (China) have agreed to commercialize BAT1706 (Bio-Thera Solutions' proposed bevacizumab biosimilar) in the United States, Europe, Canada, and other international markets. and In Aug 2020, Semglee has been launched in the United States by Biocon Biologics India, a fully integrated biosimilar firm and a subsidiary of Biocon Ltd, and Mylan NV (insulin glargine injection). As a result, all of these characteristics have been discovered to help the region's total market growth.
What Can be Explored with the Biologics Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Biologics Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Biologics
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Biologics market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Biologics market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Industry Association, Downstream Vendors, Marketing & Consulting firms, Venture Capitalists, Government & Regulatory Bodies and Investors.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Frequently Asked Questions (FAQ):1. What is the growth rate predicted for the Global Biologics Market?
The Biologics market is expected to see a CAGR of % during projected year 2021 to 2027.
2. Who are the top performing companies in Biologics Market?
Top performing companies in the Global Biologics market are Merck & Co., Inc. (United States), AbbVie Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Johnson & Johnson (United States), Pfizer Inc. (United States), AstraZeneca (United Kingdom), ABLbio (South Korea), Adimmune (Taiwan), Helius (India) and Innovent Biologics (China), to name a few.
3. What trending factors would impact Biologics Market growth most?
"FDA Regulations Revised to Make Biologics Drug Development Easier
" is seen as one of major influencing trends for Biologics Market during projected period 2021-2027.